All News

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.

Results from the CANFOUR trial of combining nadunolimab with chemotherapy appear to prolong overall survival among those with advanced or metastatic PDAC.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.

Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.

Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.

Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.

James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.